Cyrus Ghobadi MD PhD

Most small and mid-sized biotechs reach their first clinical milestone on strong science and lose years of runway getting the clinical strategy right. Artiko is founded specifically and exclusively for biopharma; I partner with biotech teams as a fractional CMO and hands-on clinical lead, bringing Fortune 500 clinical rigor at the speed and cost structure of a lean organisation. I don’t just advise. I execute. What Artiko delivers: End-to-end clinical leadership: protocols, INDs, Investigator’s Brochures, and CSRs from first draft to submission-ready First-in-Human strategies that compress timelines and protect budget across 20+ programs (immunology, oncology, respiratory, endocrinology) Safety monitoring and medical oversight with precision, leveraging AI to accelerate signal detection and decision-making Early integration of clinical pharmacology and PBPK modelling for evidence-based dose selection Senior clinical leadership in Board, partnership, and regulatory interactions — without the cost of a full-time executive The decisions made between IND submission and first patient enrolled determine whether your Phase 2 readout is compelling — or inconclusive. By then, it is expensive to fix. As Board Advisor to Avenio AI, I also work at the forefront of AI-driven clinical development, enabling faster, higher-quality protocol design and execution. I take on a limited number of engagements. If your program is approaching IND or entering Phase 1/2, let’s talk.

I work as a medical appraiser with MEDSU, supporting doctors through the appraisal and revalidation process in line with GMC requirements. I focus on helping doctors demonstrate safe, effective, and up-to-date practice, while also identifying areas for growth. Since I began working with MEDSU, I have had the privilege of appraising over 1,800 GMC-registered doctors from across the globe. They work in a wide range of roles as clinicians, scientists, and leaders, all contributing in meaningful ways to patient care and the advancement of medicine. It has been genuinely rewarding to support them through their appraisal and revalidation journey, and I’m proud to have played a part in their continued development. Overall, I see appraisal as an opportunity not just for governance, but for professional growth, reflection, and maintaining high standards of patient care.

Medical Science Director in The Respiratory, Immunology and Auto-Immune (RIA), Translational Medicine Unit (TMU). Unit (TMU). Reporting to the Vice President, this is a business-critical and influential role with high level accountabilities. I am involved with the early clinical development of at least 2 compounds in the portfolio.The aim is to move treatment of Respiratory disease beyond symptom control to disease modification and cure. I am also involved in delivering the Medical Scientific strategies of the Clinical Development Plan (CDP) to the project team. I am accountable for the clinical risk/benefit, scientific and value content and delivery of the Medical Science components of the project as well as design, conduct monitoring, data interpretation and reporting of individual clinical trials whilst ensuring projects adhere to Good Clinical Practice and regulatory requirements. I have have responsibility and accountability for delivering clinical work which establishes the platform of evidence in human which credentials the target linkage to human disease and find evidence that a pathway drives a disease and the phenotype of patients in whom these pathways are activated. In addition, I will use their clinical/scientific acumen to maximize the efficient delivery of the highest quality clinical data in support of the ongoing strategy.

The unit is part of University Hospital South Manchester (UHSM) and centre of excellence for Translational Medicine and Phase 1-3 clinical development mainly within respiratory field.

The Simcyp Simulator, now part of CERTARA, is a platform for modelling & simulation of pharmacokinetics and pharmacodynamics in virtual humans and laboratory animals. As Senior Scientist, my roles and responsibilities as part of a team were to provides services and consults for large pharmaceutical companies where I was involved with many aspects of drug development and designing clinical study from first in human - later stages. I was also the team leader for the on-site training of clients that involved visiting pharmaceutical companies and communicating with KOMs on latest scientific concepts in translation of in vitro data - in vivo expectations as well as business development. During this period I visited most major pharmaceutical sites in US, Europe and Japan, such as Abbott, AstraZeneca, Daiichi-Sankyo, Eli Lilly, Johnson & Johnson, Lundbeck, Merck, Novartis, Nycomed, Otsuka, Pfizer SanofiAventis, Takeda and UCB Pharma.

The focus of this PhD project was on optimisation of drug therapy in female infertility led by Professor William Ledger (clinical aspects) and Professor Rostami (translational aspects and systems pharmacology). The group has an international reputation in Pharmacogenomics and Pharmacokinetics, and led for many years by Professor Geoff Tucker. I learned many aspects of doing research including design and conduct of prospective clinical studies, retrospective data analysis, laboratory-based experiment and computer-based investigation by modelling and simulation.